Influenza Prevention in the Era of COVID-19

May 21, 2020

Because the annual in-person National Adult and Influenza Immunization Summit meeting was cancelled in response to COVID-19 recommendations, a virtual Summit meeting was held on May 21, 2020. With its focus on influenza, the virtual meeting mirrored the typical final day of the in-person Summit. Please check below to view a recording of the entire virtual event, access individual presentations shared during the meeting, or review questions and answers provided by the presenters.

Influenza Prevention in the Era of COVID-19 Vaccine

 

SESSION ONE: Opening and CDC Influenza Updates

 

• Opening Welcome
  L.J Tan, MS, PhD
  Chief Strategy Officer
  Immunization Action Coalition (IAC)
  Ilka Chavez, MPA
  Senior Public Health Advisor, Office of Infectious Disease and HIV/AIDS Policy
  Department of Health and Human Services (OIDP-HHS)

• Setting the Stage (no slides)
  Nancy Messonnier, MD
  Director, National Center for Immunizations and Respiratory Diseases
  Centers for Disease Control and Prevention (CDC)
  

• Preview of CDC Vaccination Plans for the 2020–21 Influenza Season
  Ram Koppaka, MD, PhD
  Associate Director for Adult Immunization, Immunization Services Division
  Centers for Disease Control and Prevention (CDC)

• ACIP Influenza Update
  Lisa Grohskopf, MD, MPH
  Medical Officer, Influenza Division
  Centers for Disease Control and Prevention (CDC)

• Review of 2019–20 Vaccine Effectiveness Estimates
  Jessie Chung, MPH
  Epidemiologist, Influenza Division
  Centers for Disease Control and Prevention (CDC)

• 2020–2021 Flu Vaccine Communications
  Erin Burns, MA
  Lead, Influenza Division Communications Team
  Centers for Disease Control and Prevention (CDC)

 

SESSION TWO: Partner Organization Updates

 

• Adult IIS Project
  Rebecca Coyle, MSEd
  Executive Director
  American Immunization Registry Association (AIRA)

• 2020–2021 AAFP Influenza Plan
  Amy Mullins, MD
  Medical Director, Quality and Science
  American Academy of Family Physicians (AAFP)
  Bellinda Schoof, MHA, CPHQ, CAE
  Director, Health of the Public and Science
  American Academy of Family Physicians (AAFP)
  Pamela Carter-Smith, MPA
  Clinical Policies Strategist, Health of the Public and Science
  American Academy of Family Physicians (AAFP)

• Influenza Update
  Flor Munoz, MD, FAAP
  Associate Professor of Pediatrics,
  Infectious Diseases, Molecular Virology, and Microbiology
  Baylor College of Medicine,
  American Academy of Pediatrics (AAP)

• ACOG Influenza Season Vaccination Efforts
  Debra Hawks, MPH
  Senior Director, Practice Activities, Obstetrics and Immunization
  American College of Obstetricians and Gynecologists (ACOG)

• ACP Update
  Selam Wubu, MPH
  Director, Center for Quality
  American College of Physicians (ACP)

• Preparing for Routine Vaccinations During COVID-19: Perspectives from Pharmacists
  Mitch Rothholz, RPh, MBA
  Chief Strategy Officer
  American Pharmacists Association (APhA)

 

SESSION THREE: Influenza Vaccine Manufacturer Updates

 

• Injection Device Planning for the 2020–2021 Flu Season
  Janice Adkins, MBA
  Associate Director, Global Marketing, Medication Delivery Solutions
  BD

• The Role of Distributors in the Flu Products Supply Channel
  Elizabeth Hilla
  Senior Vice President
  Health Industry Distributors Association (HIDA)

• FluMist: Meeting the Challenges of the ‘20–’21 Flu Season
  Alan Green
  U.S. Commercial Lead, FluMist
  AstraZeneca

• GSK Influenza Vaccines
  Chris Jennings, MBA
  U.S. Flu Marketing Lead, U.S. Vaccines
  GlaxoSmithKline (GSK)

• Sanofi Pasteur Influenza Vaccines
  Chris Whitman
  Vice President, Influenza Franchise, U.S.
  Sanofi Pasteur

• On the Front Line™ Against Influenza
  David Ross, MBA, ACE
  Vice President, Commercial Operations, North America
  Seqirus

• Closing Remarks (no slides)
  L.J Tan, M.S, PhD
  Chief Strategy Officer
  Immunization Action Coalition (IAC)

(to be posted soon)
Questions and Answers from the presenters